At a workshop on managing conflicts of interest in medicine, Chris Winchester, CEO of Oxford PharmaGenesis and co-founder of Open Pharma, argued for openness.
Research discoverability – insights from the OAI 11 CERN-UNIGE Workshop on Innovations in Scholarly Communication
When it comes to driving change in academic publishing practices, much of the focus is on making research outputs freely available to all those who wish to access them. However, open access publishing is just the tip of the iceberg.
Clinical trial transparency – time for pharma to go above and beyond?
On 11–12 June 2019, over 60 pharma stakeholders met in Amsterdam at the 8th Annual Publication and Clinical Trial Transparency Conference to discuss the evolving landscape of clinical trial transparency.
GPCAP recommendations strengthen the credibility of medical conference presentations
The Good Practice for Conference Abstracts and Presentations (GPCAP) recommendations have been developed to address the challenges faced by industry professionals and authors when preparing abstracts and presentations for academic conferences.
Clinical trial transparency – who’s watching?
On 15 May 2019, the Center for Biomedical Research Transparency (CBMRT) brought the stakeholders in academic publishing together to share their varying perspectives on research transparency and accessibility at the European Biomedical Transparency Summit (BMTS), in Paris.
New Open Pharma resource: open access educational materials
New Open Pharma resource: open access educational materials
Using metadata to make open access science discoverable
In January 2019, Open Pharma core members and supporters attended a roundtable meeting, hosted by The BMJ at its Head Office at BMA House in London.
ISMPP U webinar: insights and perspectives on open access in medical publishing
Last week’s ISMPP-U webinar ‘Open Access and Medical Publishing’, developed by the Medical Publishing Insights & Practices (MPIP) initiative and Open Pharma and moderated by LaVerne Mooney (Pfizer) and Chris Winchester (Oxford PharmaGenesis), aimed to define the key elements of open access policies, to provide insight into the changing publishing environment and to understand the perspectives of non-commercial and commercial stakeholders on open access publishing.
Guest post: How to make research open to everybody: a case study on ecancer
In recent years, open access has provided new audiences, including patients, the general public and doctors in low and middle income countries (LMICs), with direct, free access to the results of scientific research.
MPIP launches new open access toolkit
A new reference site from Medical Publishing Insights and Practices (MPIP) aims to educate its users on the ins and outs of open access as part of its commitment to improving research transparency in pharma. With open access everywhere nowadays, it is very important to know what it is and how it works. However, this … Continue reading MPIP launches new open access toolkit